Low Interest Rates Drive Demand for Corporate Bonds: Harbour Investment Partners Offers Unmatched Opportunities
Sydney, AU, Jan. 03, 2025 (GLOBE NEWSWIRE) -- In a global financial…
Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…
RadNet Secures Commitments to Amend its Credit Facility, Resulting in 0.25% Reduction in Interest Rates
November 22, 2024 11:00 ET | Source: RadNet, Inc. LOS ANGELES, Nov.…